Last updated: October 6, 2023
Sponsor: MeiraGTx, LLC
Overall Status: Active - Recruiting
Phase
1/2
Condition
Parkinson's Disease
Treatment
Sham Surgery
AAV-GAD Dose 1
AAV-GAD Dose 2
Clinical Study ID
NCT05603312
Ages 25-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Confirmed Parkinson's Disease
- Levodopa responsiveness for at least 12 months
- UPDRS Part 3 score of ≥25 points in the "off" state
Exclusion
Exclusion Criteria:
- Past history of brain surgery to treat Parkinson's Disease
- Any history of cerebral insult or central nervous system infection
- Atypical Parkinson's Disease
- Focal or lateralized neurologic deficits
- Evidence of significant medical or psychiatric disorders
- Cognitive impairment as defined by Montreal Cognitive Assessment (MoCA)≤20
- Beck Depression Inventory-II score of ≥ 20
Study Design
Total Participants: 14
Treatment Group(s): 3
Primary Treatment: Sham Surgery
Phase: 1/2
Study Start date:
October 05, 2022
Estimated Completion Date:
March 01, 2024
Study Description
Connect with a study center
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
United StatesActive - Recruiting
Columbia University Irving Medical Center
New York, New York 10032
United StatesActive - Recruiting
Weill Cornell Medicine
New York, New York 10021
United StatesActive - Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania 19107
United StatesActive - Recruiting
West Virginia University
Morgantown, West Virginia 26506
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.